This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent. Top assignee: Novo Nordisk A/s. Active years: 2015-2020.
Company Filing History:
Years Active: 2015-2020
Title: Birgitte Urso: Innovator in Therapeutic Antibodies
Introduction
Birgitte Urso is a prominent inventor based in Copenhagen, Denmark. She has made significant contributions to the field of therapeutic antibodies, particularly in the development of monoclonal antibodies targeting human NKG2D. With a total of 2 patents, her work is paving the way for advancements in medical treatments.
Latest Patents
Birgitte's latest patents include innovative isolated anti-human NKG2D monoclonal antibodies. These antibodies are designed for therapeutic applications in humans, with a focus on minimizing immune responses when administered to patients. The preferred antibodies in her patents include human monoclonal antibodies MS and 21F2. Additionally, her inventions encompass other antigen-binding molecules, such as antibody fragments and multi-specific molecules, which can be derived from these antibodies.
Career Highlights
Birgitte Urso is associated with Novo Nordisk A/S, a leading global healthcare company. Her work at Novo Nordisk has been instrumental in advancing therapeutic solutions that address critical health challenges. Her expertise in antibody development has positioned her as a key figure in the biotechnology sector.
Collaborations
Throughout her career, Birgitte has collaborated with notable colleagues, including Peter Andreas Nicolai Reumert Wagtmann and Inger Lund Pedersen. These collaborations have further enhanced her research and development efforts in the field of therapeutic antibodies.
Conclusion
Birgitte Urso's contributions to the field of therapeutic antibodies exemplify her innovative spirit and dedication to improving human health. Her patents and work at Novo Nordisk continue to influence the landscape of medical treatments.